Provided by Tiger Fintech (Singapore) Pte. Ltd.

Marker Therapeutics, Inc.

1.56
+0.350028.93%
Post-market: 1.47-0.0900-5.77%17:35 EDT
Volume:2.01M
Turnover:3.06M
Market Cap:17.65M
PE:-1.16
High:1.82
Open:1.20
Low:1.20
Close:1.21
Loading ...

Marker Therapeutics Inc. Releases Document on Lymphodepletion Enhancing MAR-T Cell Response in Lymphoma

Reuters
·
20 May

BRIEF-Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

Reuters
·
20 May

Marker Therapeutics reports evidence from Phase 1 APOLLO study

TIPRANKS
·
20 May

Marker Therapeutics Reports That Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients With Lymphoma

THOMSON REUTERS
·
20 May

Canaccord Genuity Sticks to Its Buy Rating for Marker Therapeutics (MRKR)

TIPRANKS
·
19 May

Marker Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Marker Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
09 May

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference

GlobeNewswire
·
01 Apr

Marker Therapeutics (MRKR) Receives a Buy from Canaccord Genuity

TIPRANKS
·
01 Apr

Marker Therapeutics Price Target Maintained With a $12.50/Share by WBB Securities

Dow Jones
·
01 Apr

Marker Therapeutics FY Net Income USD -10.7 Million

THOMSON REUTERS
·
31 Mar

Press Release: Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Dow Jones
·
31 Mar

Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
21 Mar

Marker Therapeutics up 8% After Canaccord Genuity Initiates Coverage With "Buy" Rating

THOMSON REUTERS
·
06 Mar

Canaccord Genuity Initiates Marker Therapeutics at Buy With $8 Price Target

MT Newswires Live
·
05 Mar

Marker Therapeutics initiated with a Buy at Canaccord

TIPRANKS
·
05 Mar

Marker Therapeutics initiated with a Buy at Brookline

TIPRANKS
·
11 Feb

BRIEF-Marker Therapeutics Inc Files For Resale Of Up To 10.1 Million Shares By The Selling Stockholders - SEC Filing

Reuters
·
11 Jan

Marker Therapeutics Inc Files for Resale of up to 10.1 Mln Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS
·
11 Jan

Marker Therapeutics to Raise $16.1 Million in Private Placement

MT Newswires Live
·
20 Dec 2024